Medivation Provides Clinical Development Update For Its Three Programs
16th Nov 2006, 18:21 GMT
Medivation, Inc. (Amex: MDV) today announced updated clinical development plans and milestones for its three programs in Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. [click link for full article]
Latest news from Health News from Medical News Today:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes